AR018101A1 - UNA REGION VARIABLE DE UNA CADENA LIGERA Y DE UNA CADENA PESADA, MOLECULAS DE ACIDO NUCLEICO QUE LAS CODIFICAN, VECTORES DE EXPRESIoN, ANTICUERPOS QUIMERICOS QUE SE ENLAZAN A CD40 HUMANO, ANTICUERPOS HUMANIZADOS Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS CADENAS. - Google Patents

UNA REGION VARIABLE DE UNA CADENA LIGERA Y DE UNA CADENA PESADA, MOLECULAS DE ACIDO NUCLEICO QUE LAS CODIFICAN, VECTORES DE EXPRESIoN, ANTICUERPOS QUIMERICOS QUE SE ENLAZAN A CD40 HUMANO, ANTICUERPOS HUMANIZADOS Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS CADENAS.

Info

Publication number
AR018101A1
AR018101A1 ARP990100704A ARP990100704A AR018101A1 AR 018101 A1 AR018101 A1 AR 018101A1 AR P990100704 A ARP990100704 A AR P990100704A AR P990100704 A ARP990100704 A AR P990100704A AR 018101 A1 AR018101 A1 AR 018101A1
Authority
AR
Argentina
Prior art keywords
antibodies
human
expression vectors
humanized
heavy chain
Prior art date
Application number
ARP990100704A
Other languages
English (en)
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of AR018101A1 publication Critical patent/AR018101A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Los solicitantes han descubierto nuevos anticuerpos CD40 anti-humanos quiméricos y humanizados que bloquean la interaccion entre gp39 y CD40. Losanticuerpos CD40 son efectivos en la modulacion de respuestas inmunes humorales contra antígenos quedepe nden de la célula T, artritis inducida por colágeno, ytransplante de piel, y también son utiles por sus propiedades anti-inflamatorias. Dichos anticuerpos quiméricos comprenden: (a) una cadena ligera, quecomprende toda o una porcionbiologicamente ac tiva de una secuencia de aminoácidos comos e muestra en la SEC ID Ns1 (Figura 4a); o (b) una cadena pesada quecomprende toda o una porcion biologicamente activa de una secuencia de aminoácidos como se muestra en la SEC ID Ns:2(Figura 4b); o (c) amba s (a) y (b). Ademásse revelan las moléculas que codifican las cadenas largas ligeras y pesadas de los anticuerpos quiméricos, los vectores de expresion correspondientes; losanticuerpos humanizados y las composicionesfarmacéuticas que contienen dicho s anticuerpos y quiméricos y humanizados.
ARP990100704A 1998-02-19 1999-02-23 UNA REGION VARIABLE DE UNA CADENA LIGERA Y DE UNA CADENA PESADA, MOLECULAS DE ACIDO NUCLEICO QUE LAS CODIFICAN, VECTORES DE EXPRESIoN, ANTICUERPOS QUIMERICOS QUE SE ENLAZAN A CD40 HUMANO, ANTICUERPOS HUMANIZADOS Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS CADENAS. AR018101A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/026,291 US6051228A (en) 1998-02-19 1998-02-19 Antibodies against human CD40

Publications (1)

Publication Number Publication Date
AR018101A1 true AR018101A1 (es) 2001-10-31

Family

ID=21830976

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990100704A AR018101A1 (es) 1998-02-19 1999-02-23 UNA REGION VARIABLE DE UNA CADENA LIGERA Y DE UNA CADENA PESADA, MOLECULAS DE ACIDO NUCLEICO QUE LAS CODIFICAN, VECTORES DE EXPRESIoN, ANTICUERPOS QUIMERICOS QUE SE ENLAZAN A CD40 HUMANO, ANTICUERPOS HUMANIZADOS Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS CADENAS.

Country Status (31)

Country Link
US (3) US6051228A (es)
EP (1) EP1054692A4 (es)
JP (1) JP2002503495A (es)
KR (1) KR100564376B1 (es)
CN (1) CN1198647C (es)
AR (1) AR018101A1 (es)
AU (1) AU751064B2 (es)
BG (1) BG65010B1 (es)
BR (1) BR9908045A (es)
CA (1) CA2321165A1 (es)
CO (1) CO4830493A1 (es)
CZ (1) CZ20003008A3 (es)
EE (1) EE200000470A (es)
GE (1) GEP20033016B (es)
HU (1) HUP0100763A3 (es)
ID (1) ID25792A (es)
IL (2) IL137294A0 (es)
LT (1) LT4837B (es)
LV (1) LV12561B (es)
MY (1) MY121464A (es)
NO (1) NO20004133L (es)
NZ (1) NZ505696A (es)
PE (1) PE20000268A1 (es)
PL (1) PL197143B1 (es)
RU (1) RU2220980C2 (es)
SK (1) SK12092000A3 (es)
TR (1) TR200002405T2 (es)
TW (1) TWI226334B (es)
UA (1) UA71909C2 (es)
WO (1) WO1999042075A2 (es)
ZA (1) ZA991307B (es)

Families Citing this family (120)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US7153508B2 (en) * 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6113898A (en) * 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US7175847B1 (en) * 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
DE69731836T2 (de) * 1996-07-23 2005-12-01 Pangenetics B.V. Induzierung von t zell toleranz unter verwendung eines löslichen moleküls, dass gleichzeitig zwei kostimulierungswege blockieren kann
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
WO2000066155A1 (en) 1999-04-30 2000-11-09 La Jolla Institute For Allergy And Immunology Methods for preventing reactivation of latent virus and controlling virus replication
DK1176981T3 (da) * 1999-05-07 2006-04-10 Genentech Inc Behandling af autoimmune sygdomme med antagonister som binder til B celleoverflademarkörer
US8119101B2 (en) * 1999-05-10 2012-02-21 The Ohio State University Anti-CD74 immunoconjugates and methods of use
US8383081B2 (en) * 1999-05-10 2013-02-26 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods of use
US7074403B1 (en) * 1999-06-09 2006-07-11 Immunomedics, Inc. Immunotherapy of autoimmune disorders using antibodies which target B-cells
US7829064B2 (en) * 1999-05-10 2010-11-09 Immunomedics, Inc. Anti-CD74 immunoconjugates and methods
US6946129B1 (en) * 1999-06-08 2005-09-20 Seattle Genetics, Inc. Recombinant anti-CD40 antibody and uses thereof
AU6929100A (en) * 1999-08-23 2001-03-19 Biocrystal Limited Methods and compositions for immunotherapy of b cell involvement in promotion ofa disease condition comprising multiple sclerosis
WO2001024823A1 (en) * 1999-10-04 2001-04-12 Chiron Corporation Cd40 antagonist for treating psoriasis
EP1839674A1 (en) * 1999-10-04 2007-10-03 Novartis Vaccines and Diagnostics, Inc. CD40 antagonist for treating psoriasis
US6849425B1 (en) 1999-10-14 2005-02-01 Ixsys, Inc. Methods of optimizing antibody variable region binding affinity
WO2001034649A2 (en) * 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
GB0001448D0 (en) 2000-01-21 2000-03-08 Novartis Ag Organic compounds
GB0006398D0 (en) * 2000-03-16 2000-05-03 Novartis Ag Organic compounds
CN1450912A (zh) * 2000-04-19 2003-10-22 泰诺士公司 用于治疗牛皮癣和其它炎性皮肤病的cd40拮抗剂
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
US20030059427A1 (en) * 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
GB0020685D0 (en) 2000-08-22 2000-10-11 Novartis Ag Organic compounds
JP2004508420A (ja) * 2000-09-18 2004-03-18 アイデック　ファーマスーティカルズ　コーポレイション Ｂ細胞枯渇抗体／免疫調節性抗体の組合せを用いて自己免疫疾患を治療するための併用療法
ATE507839T1 (de) * 2001-04-02 2011-05-15 Genentech Inc Kombinationstherapie
EP2011802A3 (en) * 2001-04-27 2009-04-15 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
US20030091593A1 (en) * 2001-09-14 2003-05-15 Cytos Biotechnology Ag In vivo activation of antigen presenting cells for enhancement of immune responses induced by virus like particles
AR039067A1 (es) 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
EP1455812A4 (en) * 2001-11-26 2006-03-22 Chiron Corp TREATMENT OF ANTI-CD40 MONOCLONAL ANTIBODY FOR THE TREATMENT OF MULTIPLE SCLEROSIS
US20050069549A1 (en) 2002-01-14 2005-03-31 William Herman Targeted ligands
CA2478012C (en) * 2002-03-01 2012-06-19 Immunomedics, Inc. Internalizing anti-cd74 antibodies and methods of use
US9770517B2 (en) 2002-03-01 2017-09-26 Immunomedics, Inc. Anti-Trop-2 antibody-drug conjugates and uses thereof
US20160279239A1 (en) 2011-05-02 2016-09-29 Immunomedics, Inc. Subcutaneous administration of anti-cd74 antibody for systemic lupus erythematosus and autoimmune disease
AU2003300842A1 (en) * 2002-12-09 2004-06-30 Tolerrx, Inc. Inducing tolerance in primates
US8420086B2 (en) 2002-12-13 2013-04-16 Immunomedics, Inc. Camptothecin conjugates of anti-CD22 antibodies for treatment of B cell diseases
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
EP2149585B1 (en) * 2003-11-04 2013-08-14 Novartis Vaccines and Diagnostics, Inc. Use of antagonistic anti-CD40 monoclonal antibodies
US7674884B2 (en) * 2003-12-10 2010-03-09 Novimmune S.A. Neutralizing antibodies and methods of use thereof
US7312320B2 (en) * 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
US9550838B2 (en) 2004-02-13 2017-01-24 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
US8883160B2 (en) * 2004-02-13 2014-11-11 Ibc Pharmaceuticals, Inc. Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
EP1756162A1 (en) 2004-03-23 2007-02-28 Biogen Idec MA Inc. Receptor coupling agents and therapeutic uses thereof
AU2004324464A1 (en) * 2004-10-22 2006-05-04 Applied Molecular Evolution, Inc. Methods of optimizing antibody variable region binding affinity
US9707302B2 (en) 2013-07-23 2017-07-18 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
US10058621B2 (en) 2015-06-25 2018-08-28 Immunomedics, Inc. Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
LT1868635T (lt) * 2005-04-06 2017-07-10 Bristol-Myers Squibb Company Imuninių sutrikimų, susijusių su transplantato persodinimu, gydymo būdas tirpiomis mutantinėmis ctla4 molekulėmis
US8475794B2 (en) 2005-04-06 2013-07-02 Ibc Pharmaceuticals, Inc. Combination therapy with anti-CD74 antibodies provides enhanced toxicity to malignancies, Autoimmune disease and other diseases
US8349332B2 (en) 2005-04-06 2013-01-08 Ibc Pharmaceuticals, Inc. Multiple signaling pathways induced by hexavalent, monospecific and bispecific antibodies for enhanced toxicity to B-cell lymphomas and other diseases
PT1889065E (pt) 2005-05-18 2013-09-27 Novartis Ag Métodos para o diagnóstico e tratamento de doenças tendo uma componente autoimune e/ou inflamatória
RU2407544C2 (ru) * 2005-05-26 2010-12-27 Сиэтл Дженетикс, Инк. Гуманизированные анти-cd40-антитела и способы их применения
US7668387B2 (en) * 2005-06-20 2010-02-23 Intel Corporation Selective local transient improvement and peaking for video sharpness enhancement
PT2298815E (pt) * 2005-07-25 2015-07-16 Emergent Product Dev Seattle Moléculas de ligaçao especificas para cd37 e especificas para cd20
WO2007033369A2 (en) * 2005-09-14 2007-03-22 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring c4d on platelets
US20070202549A1 (en) * 2005-09-14 2007-08-30 University Of Pittsburgh Assessing risk of cerebrovascular thrombosis by measuring C4d on platelets
US20080131914A1 (en) * 2005-09-14 2008-06-05 Ahearn Joseph M Assessing risk of cerebrovascular thrombosis by measuring c4d
CN101325970B (zh) 2005-11-01 2013-08-14 诺华有限公司 抗cd40抗体的应用
JP5290152B2 (ja) 2006-04-21 2013-09-18 ノバルティス アーゲー 拮抗剤抗ｃｄ４０抗体薬学的組成物
CA2652599C (en) * 2006-05-03 2019-09-24 Ross Kedl Cd40 agonist antibody/type1 interferon synergistic adjuvant combination, conjugates containing and use thereof as a therapeutic to enhance cellular immunity
EP1854810A1 (en) * 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
JP5118139B2 (ja) * 2006-08-04 2013-01-16 バクスター・インターナショナル・インコーポレイテッド 新規発症自己免疫性糖尿病を予防および／または逆転させるためのマイクロスフィアに基づく組成物
US20090074711A1 (en) * 2006-09-07 2009-03-19 University Of Southhampton Human therapies using chimeric agonistic anti-human cd40 antibody
PT2176296E (pt) 2007-07-16 2012-05-14 Genentech Inc Anticorpos e imunoconjugados anti-cd79b e métodos de utilização
JP2010533495A (ja) 2007-07-16 2010-10-28 ジェネンテック， インコーポレイテッド ヒト化ＣＤ７９ｂ抗体およびイムノコンジュゲートならびにそれらの使用
MY157403A (en) 2008-01-31 2016-06-15 Genentech Inc Anti-cd79b antibodies and immunoconjugates and methods of use
AU2010222930B2 (en) 2008-07-16 2013-07-25 Baylor Research Institute Antigen presenting cell targeted cancer vaccines
CN102770457A (zh) * 2009-03-10 2012-11-07 贝勒研究院 靶向抗原呈递细胞的疫苗
EP2523680A4 (en) * 2010-01-11 2013-06-19 Ct Molecular Med & Immunology REINFORCED CYTOTOXICITY OF ANTIBODIES TO CD74 AND HLA-DR WITH INTERFERON GAMMA
HUE038788T2 (hu) 2010-03-31 2018-11-28 Boehringer Ingelheim Int Anti-CD40 antitestek
PT2569013T (pt) * 2010-05-14 2017-02-08 Univ Leland Stanford Junior Anticorpos monoclonais humanizados e quiméricos para cd47
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012125569A2 (en) 2011-03-11 2012-09-20 Beth Israel Deaconess Medical Center, Inc. Anti-cd40 antibodies and uses thereof
AR086360A1 (es) 2011-04-21 2013-12-11 Bristol Myers Squibb Co Polipeptidos anticuerpos que antagonizan cd40
MX339239B (es) 2011-04-29 2016-05-18 Apexigen Inc Anticuerpos anti-cd40 y metodos de uso.
GB201115280D0 (en) 2011-09-05 2011-10-19 Alligator Bioscience Ab Antibodies, uses and methods
TWI585102B (zh) 2011-10-13 2017-06-01 必治妥美雅史谷比公司 拮抗ｃｄ４０ｌ之抗體多肽
US9757458B2 (en) 2011-12-05 2017-09-12 Immunomedics, Inc. Crosslinking of CD22 by epratuzumab triggers BCR signaling and caspase-dependent apoptosis in hematopoietic cancer cells
US9192664B2 (en) 2011-12-05 2015-11-24 Immunomedics, Inc. Therapeutic use of anti-CD22 antibodies for inducing trogocytosis
CN104918957B (zh) 2012-10-30 2018-11-16 埃派斯进有限公司 抗-cd40抗体及其使用方法
US10413539B2 (en) 2012-12-13 2019-09-17 Immunomedics, Inc. Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
US10206918B2 (en) 2012-12-13 2019-02-19 Immunomedics, Inc. Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
US9492566B2 (en) 2012-12-13 2016-11-15 Immunomedics, Inc. Antibody-drug conjugates and uses thereof
US10137196B2 (en) 2012-12-13 2018-11-27 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
CA3177936A1 (en) 2012-12-13 2014-06-19 Immunomedics, Inc. Dosages of immunoconjugates of antibodies and sn-38 for improved efficacy and decreased toxicity
US9931417B2 (en) 2012-12-13 2018-04-03 Immunomedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US10744129B2 (en) 2012-12-13 2020-08-18 Immunomedics, Inc. Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
US9107960B2 (en) 2012-12-13 2015-08-18 Immunimedics, Inc. Antibody-SN-38 immunoconjugates with a CL2A linker
US11253606B2 (en) 2013-07-23 2022-02-22 Immunomedics, Inc. Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
EP3992210A1 (en) 2014-01-13 2022-05-04 Baylor Research Institute Novel vaccines against hpv and hpv-related diseases
US9139649B2 (en) 2014-02-25 2015-09-22 Immunomedics, Inc. Humanized anti-CD22 antibody
WO2015134988A1 (en) 2014-03-07 2015-09-11 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize cd40 to treat ibd
WO2016023960A1 (en) 2014-08-12 2016-02-18 Alligator Bioscience Ab Combination therapies with anti cd40 antibodies
JP6716544B2 (ja) * 2014-09-16 2020-07-01 ユナイテッド・バイオメディカル・インコーポレーテッドＵｎｉｔｅｄ Ｂｉｏｍｅｄｉｃａｌ Ｉｎｃｏｒｐｏｒａｔｅｄ 競合的ｈｉｖ侵入阻害を媒介するｃｄ４に対するモノクローナル抗体によるｈｉｖ感染の処置および機能的治癒
CA3069221C (en) 2014-09-23 2023-04-04 Genentech, Inc. Methods of using anti-cd79b immunoconjugates
AU2015339128C1 (en) 2014-10-29 2021-12-16 Seagen Inc. Dosage and administration of non-fucosylated anti-CD40 antibodies
KR102656470B1 (ko) 2014-12-10 2024-04-09 리전츠 오브 더 유니버스티 오브 미네소타 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
EP3286224A4 (en) 2015-04-22 2018-11-14 Immunomedics, Inc. Isolation, detection, diagnosis and/or characterization of circulating trop-2-positive cancer cells
US10174121B2 (en) * 2015-05-29 2019-01-08 Abbvie, Inc. Anti-CD40 antibodies
US10195175B2 (en) 2015-06-25 2019-02-05 Immunomedics, Inc. Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
CN116063481A (zh) 2015-09-04 2023-05-05 普里玛托普医疗股份有限公司 人源化抗-cd40抗体及其用途
CN109069622A (zh) 2015-09-30 2018-12-21 詹森生物科技公司 特异性结合人cd40的拮抗性抗体和使用方法
CN108601841A (zh) 2016-02-10 2018-09-28 免疫医疗公司 Abcg2抑制剂与sacituzumab govitecan(immu-132)的组合克服表达trop-2的癌中对sn-38的抗性
EP3426271A4 (en) 2016-03-10 2019-10-16 Cold Genesys, Inc. METHODS OF TREATING SOLID OR LYMPHATIC TUMORS BY POLYTHERAPY
RU2725292C2 (ru) 2016-04-27 2020-06-30 Иммьюномедикс, Инк. Эффективность конъюгатов антитела против trop-2 с лекарственным средством sn-38 для терапии рецидивирующих/рефрактерных к ингибиторам контрольной точки опухолей
JP7261379B2 (ja) 2016-06-20 2023-04-20 カイマブ・リミテッド 抗ｐｄ－ｌ１抗体
JP2020512314A (ja) 2017-03-27 2020-04-23 イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療
EP3606964A4 (en) 2017-04-03 2020-12-09 Immunomedics, Inc. SUBCUTANE ADMINISTRATION OF ANTIBODY DRUG CONJUGATES FOR CANCER THERAPY
US10610585B2 (en) 2017-09-26 2020-04-07 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for treating and preventing HIV
KR20210033029A (ko) 2018-07-20 2021-03-25 유큐(베이징) 바이오파마 코., 엘티디 항-cd40 항체 및 그의 용도
US20200190163A1 (en) * 2018-10-26 2020-06-18 Lijun Wu Humanized bcma-car-t cells
KR20210109520A (ko) * 2018-12-28 2021-09-06 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항체 및 이의 용도
CN111454364B (zh) * 2019-03-04 2021-03-02 北京天广实生物技术股份有限公司 结合cd40的抗体及其用途
WO2021043206A1 (zh) * 2019-09-03 2021-03-11 百奥泰生物制药股份有限公司 一种抗tigit免疫抑制剂及应用
CN113563473A (zh) 2020-04-29 2021-10-29 三生国健药业（上海）股份有限公司 四价双特异性抗体、其制备方法和用途
CN111763259B (zh) * 2020-09-03 2020-12-15 北京百奥赛图基因生物技术有限公司 抗cd40抗体及其用途
WO2023025248A1 (zh) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
US20230203176A1 (en) * 2021-09-17 2023-06-29 Novartis Ag Methods For Prevention Of Graft Rejection In Xenotransplantation
US20240190978A1 (en) 2022-11-15 2024-06-13 CSBioAsset LLC Compositions and methods for immunomodulatory bifunctional fusion molecules

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU3226593A (en) * 1991-11-26 1993-06-28 Regents Of The University Of California, The Cloning vectors for expressing pcr generated variable regions as complete heavy and/or light chain(s)
US5874082A (en) * 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
US5397703A (en) * 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
DE69624436T2 (de) * 1995-04-08 2003-08-28 Lg Chemical Ltd Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie
US6051228A (en) * 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
KR20000034847A (ko) * 1998-11-17 2000-06-26 성재갑 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물

Also Published As

Publication number Publication date
KR100564376B1 (ko) 2006-03-27
CN1307484A (zh) 2001-08-08
JP2002503495A (ja) 2002-02-05
LV12561B (en) 2001-03-20
WO1999042075A3 (en) 1999-10-14
LT4837B (lt) 2001-08-27
UA71909C2 (en) 2005-01-17
EE200000470A (et) 2001-12-17
PL197143B1 (pl) 2008-03-31
PE20000268A1 (es) 2000-06-15
CZ20003008A3 (cs) 2001-10-17
BR9908045A (pt) 2000-12-26
HUP0100763A3 (en) 2006-06-28
MY121464A (en) 2006-01-28
PL342668A1 (en) 2001-07-02
LT2000080A (en) 2001-04-25
GEP20033016B (en) 2003-07-25
IL137294A0 (en) 2001-07-24
AU751064B2 (en) 2002-08-08
CA2321165A1 (en) 1999-08-26
NO20004133L (no) 2000-10-18
WO1999042075A2 (en) 1999-08-26
TR200002405T2 (tr) 2000-11-21
US6413514B1 (en) 2002-07-02
SK12092000A3 (sk) 2002-03-05
LV12561A (en) 2000-11-20
HUP0100763A2 (hu) 2001-06-28
TWI226334B (en) 2005-01-11
NO20004133D0 (no) 2000-08-18
US6312693B1 (en) 2001-11-06
NZ505696A (en) 2003-05-30
US6051228A (en) 2000-04-18
BG104778A (en) 2001-04-30
EP1054692A2 (en) 2000-11-29
RU2220980C2 (ru) 2004-01-10
BG65010B1 (bg) 2006-12-29
CN1198647C (zh) 2005-04-27
KR20010052174A (ko) 2001-06-25
ID25792A (id) 2000-11-02
EP1054692A4 (en) 2005-02-23
AU2671699A (en) 1999-09-06
CO4830493A1 (es) 1999-08-30
ZA991307B (en) 2000-09-20
IL137294A (en) 2007-08-19

Similar Documents

Publication Publication Date Title
AR018101A1 (es) UNA REGION VARIABLE DE UNA CADENA LIGERA Y DE UNA CADENA PESADA, MOLECULAS DE ACIDO NUCLEICO QUE LAS CODIFICAN, VECTORES DE EXPRESIoN, ANTICUERPOS QUIMERICOS QUE SE ENLAZAN A CD40 HUMANO, ANTICUERPOS HUMANIZADOS Y COMPOSICIONES FARMACEUTICAS QUE COMPRENDEN DICHAS CADENAS.
PT733103E (pt) Criacao de elevados titulos de vectores de aav recombinantes
Krug et al. Stability and activity of MCSP-specific chimeric antigen receptors (CARs) depend on the scFv antigen-binding domain and the protein backbone
AR241314A1 (es) Aislado de adn, vector en base en dicho aislado cultivo de celulas tratadas con dicho vector y preparacion de factor viii humano funcional.
ATE400651T1 (de) Verwendung von grünem fluoreszenzprotein
AR241654A1 (es) Procedimiento para producir activador de plasminogeno de tejido humano.
AR010662A1 (es) Plantas transgenicas que expresan delta-endotoxinas activas contra lepidopteros
PT1066060E (pt) Celulas estaminais mesenquimais como imunossupressores
HUT45557A (en) Pesticide composition containing hybrid celles of bacillus thuringiensis as active component and process for producing hybrid celles
AR046833A1 (es) Anticuerpos anti-interleuquina-10
DE69032598D1 (de) Zusammensetzungen und methoden zur synthese des b-rezeptors für das natriuretische protein und verwendungsmethoden
ES8800359A1 (es) Metodo de produccion de factor viii:c humano
NO940736L (no) DNA sekvenser som koder for gelonin polypeptid
MX9302475A (es) Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.
DE59610632D1 (de) Varianten des humanen rekombinanten interferon-gamma (rhu-ifn-gamma) mit erhöhter thermischer stabilität
DE69233463D1 (de) Expression und reinigung von kloniertem humanen alpha-fetoprotein
MX9301535A (es) Material proteinaceo biologicamente activo aislado y purificado.
DE69817180D1 (de) Zns neuroregenerative zusammensetzungen und deren verwendungen
UY24959A1 (es) Gen codificador de la cianamida hidratasa como marcador de seleccion para plantas
ATE317021T1 (de) Antisense modulierung von lfa-3
ATE322540T1 (de) Zubereitung für übertragung der aktive tumorspezifische immunisierung von einem immunisiertem allogenem knochenmarkspender
DE60027928D1 (de) MENSCHLICHES, GEBäRMUTTERKREBS-SPEZIFISCHES SUPPRESSORPROTEIN, FüR DAS PROTEIN KODIERES POLYNUKLEOTID, MIT DEM POLYNUKLEOTID TRANSFORMIERTE ZELLE UND VERFAHREN ZUR UNTERDRüCKUNG DER PROLIFERATION VON KREBSZELLEN UNTER VERWENDUNG DES EXPRESSIONSVEKTORS
BR9506666A (pt) Construçao de DNA vetor de express o replicável processo para a preparaçao de uma bactéria atenuada célula hospedeira composiçao de vacina e processo para o tratamento ou profilaxia de uma infecçao em um mamifero por exemplo um humano
SG43288A1 (en) Bacillus thuringiensis p-2 toxin gene protein and related insecticide compositions
GT199800028A (es) Metodo de purificacion de 1, 3, 5-triisopropilbenceno.

Legal Events

Date Code Title Description
FG Grant, registration